* and ** indicate significant and highly significant differences between the treatments and the control at p -values ≤ 0.05 and 0.01, respectively. 5.
Excerpts
In subgroup analyses ( Figure 5 ), we found marginally significant results favoring boys vs. girls in children aged 3 (SMD = 0.27 (95% CI 0.00, 0.54), p = 0.05) and significant results favoring boys vs. girls aged 4, 5 and 6 years (SMD = 0.58 (95% CI 0.38, 0.77), p < 0.00001; SMD = 0.59 (95% CI 0.31, 0.88), p < 0.00001; SMD = 0.81 (95% CI 0.61, 1.01), p < 0.00001), which increased with age. 3.6.
showed a trendP = 0.05
Patients with obesity had a significantly lower risk of all‐cause mortality compared to normal‐weight patients (HR 0.78; 95% CI 0.66–0.92; P = 0.003) and patients with overweight showed a trend compared to normal‐weight patients (HR 0.86; 95% CI 0.74–1.00; P = 0.05).
borderline significanceP = 0.05
Pairwise comparisons (using total shape) indicated browsers can be distinguished from mixed feeders and grazers with borderline significance ( P = 0.05, Z = 1.7 for both), and all other pairwise comparisons were nonsignificant.
To evaluate astroglial proliferation, we imaged N = 36 Tg( Gfap -luc) RML prion-infected and N = 14 uninfected mice by BLI every 7–11 days, and pre-specified that a single 500 μg dose of ASO 1, 2 or 3 would be administered after two consecutive imaging sessions showed a nominally significant ( P < 0.05 by a two-sided Kolmogorov–Smirnov test) difference in BLI between infected and uninfected mice.
showed a trendp = 0.05
The sibutramine group showed a trend toward a greater reduction in body fat percentage than the placebo group (p = 0.05).
Nonparametric Jonckheere-Terpstra test was used to analyze the differences in median PAI-1 serum levels between ordinal HY score groups from 1 to 4 and a borderline significant difference was found between the groups ( p = 0.05).
Even when the regression model was adjusted for probable confounders such as age, stage of recovery, side, and severity of lesion, BUFET was still found to be a highly significant predictor, R 2 = 0.524, with p < 0.05.
almost significantlyp = 0.05
The sequestration of miR‐185‐5p with its inhibitor increased almost significantly the expression of POSTN (fold of 1.50 ± 0.57; p = 0.05; Figure 1c ) in BSMCs; an increase which was maintained after IL‐13 addition (fold of 1.13 ± 0.06, p < 0.05; Figure 1c ).
Incorporation of EO into MSG monolayer films resulted in an increasing trend in thickness, with the 2 % EO formulation exhibiting the highest value among all treatments ( P < 0.05).
The difference in the magnitude of variance between the first and second digitization of the 2D photographs is significant only for VAR2 (.05 > p > .01) and marginally significant (.1 > p > .05) for VAR1, with absolute deviations from the means of the two replicates accounting for less than 1% of variation (Table 5 ).
The two nutrients that did not show significant linear trends had relatively low variance in that nutrient among cereals and were borderline significant (fat, p = 0.05) or had relatively few respondents that considered that nutrient (iron, n = 39).
Furthermore, a weighted polygenic risk score (PRS) made from the 18 SNPs common between the two datasets showed a nominally significant association ( P < 0.05) with the oral glucose tolerance test derived variables area under the curve (AUC) for insulin, AUC for insulin/AUC for glucose, insulin at 30 minutes and insulin sensitivity index ( S6 Table ).
In the AFR samples, we found no significant effects in any of the examined p -value thresholds, although all but one were nominally significant ( p < 0.05).
5-FU-release ( in vitro ) from 5-FU-MNEs (w/o/w, MNE1, MNE5, and MNE9 SNEDDS) were showed highly significant (p<0.05) as compared to other 5-FU-MNEs (w/o/w, SNEDDS) ( Fig. 5 A).
showed a trendP > 0.05
Compared to control group, although the numbers of postoperative analgesic pump compression in the dexmedetomidine group showed a trend of fewer, there was no significant statistical difference between the two groups (P > 0.05, Table 2 ).
monocytogenes showed a decreasing trend from 24 to 48 h ( p < 0.05), except for the dual-species suspension (1:10).
showed a trendp < 0.05
As a result, the proliferation rate in the treatment group (1.0 μM NaAsO 2 ) was significantly higher at passages 21, 28, and 35 than that in the passage-matched control group (0.0 μM NaAsO 2 ) and showed a trend of increasing passage by passage ( p < 0.05) ( Figure 1 a).
This difference was statistically significant or highly significant, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, respectively.
Unlike males, females in Central Asia (Mongolia and Kazakhstan), Southeast Asia (Maldives), North Africa and the Middle East (Iran, Kuwait, Lebanon, Palestine and Syrian Arab Republic), Central Europe (Macedonia) and Eastern Europe (Belarus, Moldova, Lithuania and Russian Federation) showed a decreasing trend in DALY (all P < 0·05).
Traits were shown in the figure if Wald ratio or MR-IVW or MR-Weighted-Median showed nominally significant (P<0.05) results.
No statistical difference (log-rank Mantel-Cox test) in tumor size could be observed between vehicle- and 3AP-treated mice for all tested 3AP concentrations including 10 mg/kg ( P = 0.90), 7.5 mg/kg ( P = 0.07), 5 mg/kg ( P = 0.59), and 2.5 mg/kg ( P = 0.18), while only slight significance was noted for the prexasertib-treated group ( P = 0.05) ( Fig. 9, F and G ).
Furthermore, highly significant differences were observed in the correlation between region and level of education in the S2 (D) group ( p < 0.05).
While there was a marginally significant positive effect of distance on F ST ( r = 0.25, p = .05), absolute divergence Dxy did not increase significantly with distance ( r = 0.24, p = .11), and pairwise genetic differentiation of Euclidean distances was borderline significant ( r = 0.21, p = .05, Figure 3a,b ; Figure S6 ).
By utilizing Spearman correlation analysis to investigate the effect of DM duration on LDD, a positive trend was observed between DM duration and severity of disc degeneration ( P < 0.05) ( Table 2 ).